EMA Withdrawn: Angiox (Bivalirudin) — The Medicines Company UK Ltd

View source ↗

Summary

Angiox (bivalirudin) has been withdrawn from the market in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Angiox (bivalirudin)

Snippet

Status: Withdrawn. Therapeutic area: Acute Coronary Syndrome. MAH: The Medicines Company UK Ltd. Decision date: 25/10/2016